These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7556305)

  • 1. Radiopharmaceuticals 1994. Nil desperandum. European Association of Nuclear Medicine Committees on Radiopharmaceuticals and Positron Emission Tomography.
    Cox PH; Meyer GJ
    Eur J Nucl Med; 1995 Jun; 22(6):563-70. PubMed ID: 7556305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The radiopharmaceutical industry and European Union regulations.
    Fallais CJ; Sivewright S; Ogle JR
    Eur J Nucl Med; 1997 Jan; 24(1):77-9. PubMed ID: 9044882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical regulation in the single European market.
    Matthews D; Wilson C
    Med Law; 1998; 17(3):401-27. PubMed ID: 9922630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
    Enzmann H; Schneider C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should Anthroposophic Medicinal Products Be Regulated in Europe?
    Michaux G
    Eur J Health Law; 2017 Mar; 24(1):46-66. PubMed ID: 29210253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a harmonized radiopharmaceutical regulatory framework in Europe?
    Decristoforo A; Peñuelas I
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):394-401. PubMed ID: 19834449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of genotoxicity of herbal medicinal products: a co-ordinated approach.
    Kelber O; Steinhoff B; Kraft K;
    Phytomedicine; 2012 Mar; 19(5):472-6. PubMed ID: 22301069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European regulations for the introduction of novel radiopharmaceuticals in the clinical setting.
    Decristoforo C; Penuelas I; Patt M; Todde S
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):135-144. PubMed ID: 28124548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licensing failure in the European decentralised procedure.
    Langedijk J; Ebbers HC; Mantel-Teeuwisse AK; Kruger-Peters AG; Leufkens HG
    Eur J Pharm Sci; 2016 May; 87():47-51. PubMed ID: 26493584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirements on efficacy of herbal medicinal products.
    Claeson P
    J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
    Permanand G; Mossialos E; McKee M
    Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.